ArticleAnnals of surgical oncology2026
Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer: Development and Validation of a Clinical-Inflammatory Nomogram.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPathological complete response (pCR) following neoadjuvant chemotherapy (NAC) predicts favorable prognosis in breast cancer. However, significant gaps remain in identifying reliable predictors of pCR. This study aimed to identify clinicopathological and inflammatory factors associated with pCR in HER2 + breast cancer and develop a predictive nomogram. PATIENTS AND
methodsWe retrospectively analyzed 460 patients with HER2+ breast cancer who received NAC at Nanchang People's Hospital (January 2017-May 2025). Patients were randomly allocated to the training or testing cohorts at a ratio of 7:3. Variables with significant associations in univariate analysis (P < 0.05) were included in multivariate logistic regression. A nomogram incorporating independent predictors was validated for its discrimination, calibration, and clinical utility.
resultsOverall pCR rate was 47.2% (217/460). Significantly higher pCR rates occurred with: age ≥ 50 years (53.4% versus < 50:38.7%), ER- (54.6% versus ER+: 39.1%), PR- (52.0% versus PR+: 36.2%), HER2 IHC3+ (51.9% versus IHC2+/FISH+: 26.2%), dual HER2 blockade (54.9% versus chemotherapy alone: 15.9%), and high platelet-to-lymphocyte ratio (PLR) (61.0% versus low: 45.1%) (all p < 0.05). Univariate analysis in the training cohort identified that the aforementioned variables were significant predictors. Multivariate analysis confirmed age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR as independent predictors. The nomogram demonstrated good discrimination (training AUC = 0.736; testing AUC = 0.689), satisfactory calibration and favorable clinical net benefit.
conclusionsAge ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR independently predict pCR in patients with HER2+ breast cancer. The nomogram provides a clinically applicable tool for pCR prediction, which may aid in optimizing personalized NAC strategies for this population.
Indexed as
Identifiers
41691084What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.